Biopharmaceutical company ArriVent focuses on bringing biopharmaceutical medicines approved in China to the U.S. and European Union. In partnership with Shanghai-based Allist Pharma, outside of China, ArriVent has the rights to the development, manufacturing and commercialization of furmonertinib, a drug that targets locally advanced or metastatic non-small-cell lung cancer.
The company ArriVent Biopharma has raised $110 million in a private stock sale, and is expected to raise more. The round will be used to advance its current pipeline and support additional company asset growth. ArriVent Biopharma has 6 investors including Boyu Capital and Lilly Asia Ventures.
ArriVent, Pennsylvania, United States, was founded by Bing Yao and Stuart Lutzker in 2021. The team globally develops top biopharma innovations from around the world to deliver important medicines to cancer patients. The company has assembled world-class life sciences professionals with proven track records of charting the most direct and expedient path to drug approval.